Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian BioSciences : Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

07/12/2021 | 07:16am EDT
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

LOS ANGELES, July 12, 2021 (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.

The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the 'gold standard' animal model to evaluate HBV cure.

Dr. Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the Board of Enochian BioSciences, said, 'As a long-time researcher, clinician, and leader of large global disease programs, I am very pleased that the FDA accepted our request to provide feedback to our Hepatitis B development program, and welcome the agency's input. We are encouraged by the novel mechanism of action, called Hijack RNA that shows promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza and HBV, and are exploring its use against HIV.'

Dr. Carol Brosgart, Clinical Professor of Medicine, Epidemiology and Biostatistics, UCSF and former Senior Advisor for Science and Policy to the Division of Viral Hepatitis at the Centers for Disease Control and Prevention, said, 'The impressive results in the premier animal model give me great hope that we are on track to develop a commercial product that could potentially cure HBV infection, a disease that causes chronic liver damage in ~350 million people globally and kills nearly 1 million people each year.' Dr. Brosgart also served as former Vice President of Clinical Research at Gilead Sciences, responsible for HIV and HBV Drug Development, and is a Board Director of Enochian BioSciences.

About Enochian BioSciences, Inc.

Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company's gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit EnochianBio.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as 'believes,' 'plans,' 'expects,' 'aims,' 'intends,' 'potential,' or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences' most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

CContact: ir@enochianbio.com

Disclaimer

Enochian Biosciences Inc. published this content on 12 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 July 2021 11:15:19 UTC.


© Publicnow 2021
All news about ENOCHIAN BIOSCIENCES, INC.
09/13ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure, Financial Statements and Ex..
AQ
09/13ENOCHIAN BIOSCIENCES : Slide Presentation Here
PU
09/13ENOCHIAN BIOSCIENCES : to Present to Investors at the H.C. Wainwright 23rd Annua..
AQ
08/30ENOCHIAN BIOSCIENCES : Distinguished Scientific and Public Health Leaders to Joi..
PU
08/30ENOCHIAN BIOSCIENCES INC : Other Events, Financial Statements and Exhibits (form..
AQ
08/30ENOCHIAN BIOSCIENCES : Distinguished Scientific and Public Health Leaders to Joi..
AQ
08/30Enochian Biosciences, Inc. Appoints Dr. Peter Piot and Dr. Richard Whitley to..
CI
08/23Dr. Anna Suk-Fong Lok, Md to Joins Enochian Biosciences’ Hepatitis B Cure Sci..
CI
08/23ENOCHIAN BIOSCIENCES : Distinguished Scientific and Clinical Leader to Join Enoc..
PU
08/16ENOCHIAN BIOSCIENCES : Entry into a Material Definitive Agreement, Financial Sta..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -11,4 M - -
Net cash 2020 1,11 M - -
P/E ratio 2020 -17,1x
Yield 2020 -
Capitalization 377 M 377 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 10
Free-Float 38,2%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.145.76%377
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850